Streetbeat News

Stock Prices

ELF

High-rolling investors are showing increased bullish activity in e.l.f. Beauty (NYSE:ELF) options, with 62% of trades being bullish. The stock is currently trading at $107.54, with a neutral RSI. Analysts have set target prices ranging from $139 to $223, indicating potential upside.

Portfolio Pulse from Benzinga Insights

October 10, 2024 | 8:16 pm

SBUX

The options market for Starbucks (NASDAQ:SBUX) shows a mix of bullish and bearish trades, with significant investors targeting a price range of $80 to $120. Current trading volume is high, and the stock price is slightly down. Analysts have mixed ratings, with price targets ranging from $76 to $118.

Portfolio Pulse from Benzinga Insights

October 10, 2024 | 8:16 pm

BTCUSD

DOGEUSD

ETHUSD

Cryptocurrency markets are trading lower following inflation data, with Bitcoin ETFs experiencing outflows and Ethereum flows remaining muted. Bitcoin, Ethereum, and Dogecoin have all seen price declines. Notable statistics include a decrease in large transaction volume and a significant number of trader liquidations. Despite the downturn, some traders view the dip as a buying opportunity, with potential scenarios for Bitcoin's price movement being discussed.

Portfolio Pulse from Khyathi Dalal

October 10, 2024 | 8:15 pm

SSSS

SuRo Capital Corp. announced its Q3 net asset value is expected to be between $6.50 and $7.00 per share. The company continues to focus on its AI strategy with significant new investments.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 8:14 pm

AORT

Artivion presented positive clinical data at the 38th European Association for Cardio-Thoracic Surgery Annual Meeting. The data from various trials show promising results for their aortic treatment products, including the AMDS DARTS and PERSEVERE trials, and the NEOS study.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 8:11 pm

HRTX

Heron Therapeutics has confirmed the availability and supply of its products CINVANTI, SUSTOL, and APONVIE as alternatives during a potential intravenous fluids shortage.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 8:10 pm

STRO

Sutro Biopharma is showcasing its next-generation ADC innovations, highlighting preclinical data for STRO-004, which shows greater anti-tumor activity and lower toxicity compared to a benchmark ADC. The company plans to submit three IND applications in the next three years.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 8:09 pm

VOXX

VOXX International reported Q2 earnings per share of $0.10, beating the estimate of $0.00, but sales of $92.49 million missed the $117.90 million estimate. This marks a significant EPS improvement from last year's loss, but a decline in sales compared to the previous year.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 8:08 pm

ALLK

Allakos shares rise following positive results from a Phase 1 study of subcutaneous AK006 in healthy volunteers.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 8:04 pm

ALLK

Allakos Inc. announced positive Phase 1 trial results for its subcutaneous AK006, showing 77% bioavailability and prolonged receptor occupancy on mast cells. The treatment was well-tolerated with a favorable safety profile. Results for intravenous AK006 in CSU patients are expected in early Q1 2025.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 8:03 pm